Nivolumab in previously untreated melanoma without BRAF mutation.

By C. Robert, Georgina V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J. Hassel, P. Rutkowski, C. McNeil, E. Kalinka‐Warzocha and 18 more. New England Journal of Medicine, 2015

5,260 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/6a8a53c7f9fd79ff959c6101698e58d58ff6123e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 (2016, background): “As a result, these agents are now approved in various tumor types such as melanoma, squamous and non-squamous NSCLC, RCC, HNSCC, bladder cancer and Hodgkin lymphomas (1-7).”
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019, background): “Subsequent phase III studies of nivolumab as monotherapy in treatment-naive and previously treated advanced melanoma yielded durable response rates of 32% and 40%, respectively [9, 11].”
Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, background): “Since then, the anti-PD-1 antibodies nivolumab and pembrolizumab have demonstrated high activity in melanoma [3,4] and subsequently many other types of cancer e prompting a ‘PDLoma’ of activity (Fig.”
Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate (2017, background): “Overall, however, response rates for single agent immune checkpoint inhibitors in solid malignancies range from 20 to 40% (1-3).”
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (2017, positive): “The impressive and durable clinical response of checkpoint blockade immunotherapy resulted in the FDA approval of ipilimumab, nivolumab, pembrolizumab, and more recently atezolizumab for the treatment of multiple types of cancer, such as melanoma, Hodgkin’s lymphoma, and lung and bladder cancers ([1”
Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, methodology): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”